Vanderbilt University Medical Center
- Type
- Teaching hospital
- Where
- Nashville, TN
- Medicare CCN
- 440039
- Received
- $27,636,786 in 3,812 records, 2020 ($1,294,121 general, $26,342,665 research)
- Source
- CMS Open Payments search ↗
On this site
- Business registration: Vanderbilt University Medical Center Fuzzy (name and state)
- Business registration: Vanderbilt University Medical Center Fuzzy (name and state)
- Business registration: VANDERBILT UNIVERSITY MEDICAL CENTER Fuzzy (name and state)
- Business registration: VANDERBILT UNIVERSITY MEDICAL CENTER Fuzzy (name and state)
- Business registration: VANDERBILT UNIVERSITY MEDICAL CENTER Fuzzy (name and state)
- Business registration: VANDERBILT UNIVERSITY MEDICAL CENTER Fuzzy (name and state)
- Business registration: VANDERBILT UNIVERSITY MEDICAL CENTER Fuzzy (name and state)
- Business registration: VANDERBILT UNIVERSITY MEDICAL CENTER, INC. Fuzzy (name and state)
- Business registration: VANDERBILT UNIVERSITY MEDICAL CENTER, INC. Fuzzy (name and state)
- Nonprofit contractor: Vanderbilt University Medical Center Fuzzy (name and state)
- Plan sponsor: VANDERBILT UNIVERSITY MEDICAL CENTER Fuzzy (name and state)
- Federal award recipient: VANDERBILT UNIVERSITY MEDICAL CENTER Fuzzy (name and state)
- Lobbying client: VANDERBILT UNIVERSITY MEDICAL CENTER Fuzzy (name and state)
- Lobbying registrant: VANDERBILT UNIVERSITY MEDICAL CENTER Fuzzy (name and state)
- Nonprofit: VANDERBILT UNIVERSITY MEDICAL CENTER Fuzzy (name and state)
- Trademark owner: VANDERBILT UNIVERSITY MEDICAL CENTER Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2020 | General payment | 196 | $1,294,121 |
| 2020 | Research payment | 3,616 | $26,342,665 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 3,616 | $26,342,665 |
| Grant | 67 | $1,035,474 |
| Space rental or facility fees (teaching hospital only) | 44 | $101,516 |
| Education | 12 | $39,278 |
| Gift | 9 | $30,920 |
| Consulting Fee | 2 | $29,600 |
| Charitable Contribution | 7 | $22,791 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 4 | $14,200 |
| Royalty or License | 48 | $11,539 |
| Honoraria | 1 | $8,500 |
| Travel and Lodging | 2 | $300 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2020-12-31 | Allergan, Inc. | $241,581 | Research payment | In-kind items and services | FLuoroMEtholone as Adjunctive Therapy for TT Surgery (FLAME) Trial | 2020 | |
| 2020-12-31 | Allergan, Inc. | $17,303 | Research payment | In-kind items and services | AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety o | 2020 | |
| 2020-12-31 | Roche Diagnostics Operations, Inc. | $12,487 | Research payment | In-kind items and services | CD cobas Reagents Device, Centralized Diagnostics | RD005298 | 2020 |
| 2020-12-31 | Allergan, Inc. | $11,944 | Research payment | In-kind items and services | A multicenter, open-label, single arm study in patients with open angle glaucoma or ocular hypertension who have not had | 2020 | |
| 2020-12-31 | Merck Sharp & Dohme LLC | $10,000 | Research payment | Cash or cash equivalent | Innovation in Medical Evidence Development and Surveillance | 2020 | |
| 2020-12-31 | Haemonetics Corporation | $9,600 | Research payment | In-kind items and services | TEG Device, Devices | INSIGHT-The illumaniting neurophyschological dysfunction and systematic inflammatory mechanisms gleaned after hospitaliz | 2020 |
| 2020-12-31 | Haemonetics Corporation | $9,600 | Research payment | In-kind items and services | TEG Device, Devices | INSIGHT-The illumaniting neurophyschological dysfunction and systematic inflammatory mechanisms gleaned after hospitaliz | 2020 |
| 2020-12-31 | Agilent Technologies, Inc. | $7,200 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2020 | ||
| 2020-12-31 | AstraZeneca Pharmaceuticals LP | $4,505 | Research payment | In-kind items and services | A Multi arm Phase Ib Open Label, Multicentre Study to Assess the Safety Tolerability Pharmacokinetics and Preliminary An | 2020 | |
| 2020-12-31 | Allergan, Inc. | $1,017 | Research payment | In-kind items and services | Clinical Trial (LIN-MD-64: Ped FC Trial 6-17 Ph3) | 2020 | |
| 2020-12-31 | Haemonetics Corporation | $720 | Research payment | In-kind items and services | TEG Device, Devices | INSIGHT-The illumaniting neurophyschological dysfunction and systematic inflammatory mechanisms gleaned after hospitaliz | 2020 |
| 2020-12-31 | AstraZeneca Pharmaceuticals LP | $542 | Research payment | In-kind items and services | FARXIGA Drug, Cardiovascular and Metabolism | A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients with Chronic | 2020 |
| 2020-12-31 | AstraZeneca Pharmaceuticals LP | $184 | Research payment | In-kind items and services | LYNPARZA Drug, Oncology | A Phase III Open Label Randomized Study to Assess the Efficacy and Safety of Olaparib Lynparza Versus Enzalutamide or Ab | 2020 |
| 2020-12-31 | AstraZeneca UK Limited | $167 | Research payment | In-kind items and services | BYDUREON Drug, Cardiovascular and Metabolism | A Phase 3 Double Blind Placebo Controlled Randomized Multi Center Study To Assess the Safety and Efficacy of Exenatide O | 2020 |
| 2020-12-31 | AstraZeneca Pharmaceuticals LP | $163 | Research payment | In-kind items and services | FARXIGA Drug, Cardiovascular and Metabolism | Forxiga HF-D1699C00001 HF rEF Outcome study | 2020 |
| 2020-12-31 | EMD Serono, Inc. | $68 | Research payment | Cash or cash equivalent | VX14-803-001 (M4344 ATRi) | An Open-Label Study of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of VX-803/M4344 as a Single | 2020 |
| 2020-12-31 | Inspire Medical Systems, Inc. | $60 | Research payment | In-kind items and services | Inspire Upper Airway Stimulation System Device, Neurology | HOME Study | 2020 |
| 2020-12-31 | Stryker Corporation | $28 | Gift | Cash or cash equivalent | NONE Device, NONE | 2020 | |
| 2020-12-31 | AstraZeneca Pharmaceuticals LP | $8 | Research payment | In-kind items and services | TAGRISSO Drug, Oncology | A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumou | 2020 |
| 2020-12-30 | Cook Incorporated | $26,250 | Research payment | Cash or cash equivalent | 2020 | ||
| 2020-12-30 | ACUMED LLC | $2,580 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Device, Hand & Wrist | 2020 | |
| 2020-12-30 | Genentech, Inc. | $1,884 | Research payment | Cash or cash equivalent | Herceptin Biological, BioOncology | MY PATHWAY | 2020 |
| 2020-12-30 | ABBVIE INC. | $1,813 | Research payment | Cash or cash equivalent | M15-566 | 2020 | |
| 2020-12-30 | ACUMED LLC | $1,517 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Device, Hand & Wrist | 2020 | |
| 2020-12-30 | ACUMED LLC | $446 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Device, Hand & Wrist | 2020 | |
| 2020-12-30 | ACUMED LLC | $85 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Device, Hand & Wrist | 2020 | |
| 2020-12-29 | BioMarin Pharmaceutical Inc. | $10,337 | Research payment | Cash or cash equivalent | Multicenter multinational study to collect consistent baseline growth measurements on pediatric patients with Achondropl | 2020 | |
| 2020-12-29 | BioMarin Pharmaceutical Inc. | $7,920 | Research payment | Cash or cash equivalent | A Phase 2 Open-Label Long-Term Extension Study to Evaluate the Safety and Efficacy of BMN 111 in Children with Achondrop | 2020 | |
| 2020-12-29 | Cook Biotech Incorporated | $7,500 | Research payment | Cash or cash equivalent | 2020 | ||
| 2020-12-29 | Karyopharm Therapeutics Inc. | $676 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | KCP-330-020 | 2020 |
| 2020-12-28 | Janssen Research & Development, LLC | $1,750 | Research payment | Cash or cash equivalent | A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Platform Study Evaluating the Efficacy and Safety | 2020 | |
| 2020-12-28 | Cochlear Americas | $570 | Research payment | Cash or cash equivalent | Nucleus Device, Implantable hearing solution | Nucleus Hybrid L24 Implant System New Enrollment Post Approval Study | 2020 |
| 2020-12-28 | Takeda Pharmaceuticals U.S.A., Inc. | $30 | Research payment | Cash or cash equivalent | A PHASE-III, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, INTERNATIONAL, MULTICENTRE STUDY TO ASSESS EF | 2020 | |
| 2020-12-28 | Takeda Pharmaceuticals U.S.A., Inc. | $14 | Research payment | Cash or cash equivalent | A PHASE-III, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, INTERNATIONAL, MULTICENTRE STUDY TO ASSESS EF | 2020 | |
| 2020-12-24 | AstraZeneca Pharmaceuticals LP | $141,440 | Research payment | Cash or cash equivalent | Mechanistic investigation of lead Astrazeneca licensed antibodies | 2020 | |
| 2020-12-24 | Otsuka Pharmaceutical Development & Commercialization, Inc. | $54,832 | Research payment | Cash or cash equivalent | A phase 1b, Single-blind, Placebo-controlled, Adaptive design, Outpatient Trial to Assess the effects of Single Oral Tab | 2020 | |
| 2020-12-24 | Intercept Pharmaceuticals, Inc. | $8,814 | Research payment | Cash or cash equivalent | OCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY | 1011866 | 2020 |
| 2020-12-24 | Astellas Pharma Global Development | $5,778 | Research payment | Cash or cash equivalent | XOSPATA Drug, ONCOLOGY | PHASE 1/2 STUDY OF ASP2215 (GILTERITINIB) COMBINED WITH ATEZOLIZUMAB IN PATIENTS WITH RELAPSED OR TREATMENT REFRACTORY F | 2020 |
| 2020-12-24 | Astellas Pharma Global Development | $3,765 | Research payment | Cash or cash equivalent | XOSPATA Drug, ONCOLOGY | PHASE 1/2 STUDY OF ASP2215 (GILTERITINIB) COMBINED WITH ATEZOLIZUMAB IN PATIENTS WITH RELAPSED OR TREATMENT REFRACTORY F | 2020 |
| 2020-12-24 | Intercept Pharmaceuticals, Inc. | $2,587 | Research payment | Cash or cash equivalent | 1009742 | 2020 | |
| 2020-12-24 | Janssen Research & Development, LLC | $1,682 | Research payment | Cash or cash equivalent | A Double-blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of Intranasal Esketamine for th | 2020 | |
| 2020-12-24 | Deciphera Pharmaceuticals Inc. | $203 | Research payment | Cash or cash equivalent | QINLOCK Drug, ONCOLOGY | INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE | 2020 |
| 2020-12-23 | Gilead Sciences, Inc. | $8,023 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilof | 2020 | |
| 2020-12-23 | PFIZER INC. | $2,768 | Research payment | Cash or cash equivalent | VYNDAQEL Drug, CARDIOVASCULAR | A PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND EXTENSION STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS ME | 2020 |
| 2020-12-23 | IRONWOOD PHARMACEUTICALS, INC | $1,613 | Research payment | Cash or cash equivalent | C3718-301 | 2020 | |
| 2020-12-23 | Kite Pharma, Inc. | $1,609 | Research payment | Cash or cash equivalent | A Phase 2 Study Evaluating the Safety and Efficacy of KTE-C19 in high risk 1st Line DLBCL | 2020 | |
| 2020-12-23 | Kite Pharma, Inc. | $1,605 | Research payment | Cash or cash equivalent | Yescarta Drug, CELLT | A Phase 2 Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination wit | 2020 |
| 2020-12-23 | IRONWOOD PHARMACEUTICALS, INC | $1,500 | Research payment | Cash or cash equivalent | C3718-301 | 2020 | |
| 2020-12-23 | Gilead Sciences, Inc. | $1,500 | Research payment | Cash or cash equivalent | Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib | 2020 | |
| 2020-12-23 | ABBVIE INC. | $1,500 | Research payment | Cash or cash equivalent | SKYRIZI Biological, IMMUNOLOGY | M16-066 | 2020 |
| 2020-12-23 | Gilead Sciences, Inc. | $1,494 | Research payment | Cash or cash equivalent | Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib | 2020 | |
| 2020-12-23 | SEAGEN INC. | $1,420 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | 2020 |
| 2020-12-23 | JAZZ PHARMACEUTICALS INC. | $1,395 | Research payment | Cash or cash equivalent | DEFITELIO Drug, HEMATOLOGY/ONCOLOGY | A PHASE 3, RANDOMIZED, ADAPTIVE STUDY COMPARING THE EFFICACY AND SAFETY OF DEFIBROTIDE VS BEST SUPPORTIVE CARE IN THE PR | 2020 |
| 2020-12-23 | Gilead Sciences, Inc. | $1,322 | Research payment | Cash or cash equivalent | Harvoni Drug, HCV | A Long Term Follow-up Registry for Subjects with Cirrhosis Who Achieve a Sustained Virologic Response to Treatment for H | 2020 |
| 2020-12-23 | Gilead Sciences, Inc. | $1,310 | Research payment | Cash or cash equivalent | A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Crohn's Disease | 2020 | |
| 2020-12-23 | JAZZ PHARMACEUTICALS INC. | $1,000 | Research payment | Cash or cash equivalent | DEFITELIO Drug, HEMATOLOGY/ONCOLOGY | A PHASE 3, RANDOMIZED, ADAPTIVE STUDY COMPARING THE EFFICACY AND SAFETY OF DEFIBROTIDE VS BEST SUPPORTIVE CARE IN THE PR | 2020 |
| 2020-12-23 | Regeneron Pharmaceuticals, Inc. | $250 | Charitable Contribution | Cash or cash equivalent | 2020 | ||
| 2020-12-22 | Novo Nordisk AS | $5,538 | Research payment | Cash or cash equivalent | Esperoct Biological, Hemophilia | NN7088-4410 | 2020 |
| 2020-12-22 | Novo Nordisk AS | $5,459 | Research payment | Cash or cash equivalent | RYBELSUS Drug, Diabetes | EX9924-4473 | 2020 |
| 2020-12-22 | Novo Nordisk AS | $2,056 | Research payment | Cash or cash equivalent | REBINYN Biological, Hemophilia | NN7999-3895 | 2020 |
| 2020-12-22 | Novo Nordisk AS | $1,963 | Research payment | Cash or cash equivalent | Ozempic Drug, Diabetes | NN9535-4352 | 2020 |
| 2020-12-22 | Novo Nordisk AS | $1,423 | Research payment | Cash or cash equivalent | NN7415-4307 | 2020 | |
| 2020-12-22 | Novo Nordisk AS | $1,332 | Research payment | Cash or cash equivalent | Ozempic Drug, Diabetes | NN9535-4352 | 2020 |
| 2020-12-22 | Novo Nordisk AS | $1,311 | Research payment | Cash or cash equivalent | Ozempic Drug, Diabetes | NN9535-4321 | 2020 |
| 2020-12-22 | Novo Nordisk AS | $849 | Research payment | Cash or cash equivalent | NN7415-4322 | 2020 | |
| 2020-12-22 | Merck Sharp & Dohme LLC | $524 | Research payment | Cash or cash equivalent | MK-7339 Drug, ONCOLOGY | A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Olaparib Alone or in Combination With Beva | 2020 |
| 2020-12-22 | Novo Nordisk AS | $130 | Research payment | Cash or cash equivalent | RYBELSUS Drug, Diabetes | EX9924-4473 | 2020 |
| 2020-12-22 | Novo Nordisk AS | $15 | Research payment | In-kind items and services | NN7415-4307 | 2020 | |
| 2020-12-22 | Novo Nordisk AS | $15 | Research payment | In-kind items and services | NN7415-4307 | 2020 | |
| 2020-12-22 | Novo Nordisk AS | $15 | Research payment | In-kind items and services | NN7415-4307 | 2020 | |
| 2020-12-22 | Novo Nordisk AS | $15 | Research payment | In-kind items and services | NN7415-4307 | 2020 | |
| 2020-12-22 | Novo Nordisk AS | $15 | Research payment | In-kind items and services | NN7415-4307 | 2020 | |
| 2020-12-22 | Novo Nordisk AS | $15 | Research payment | In-kind items and services | NN7415-4307 | 2020 | |
| 2020-12-22 | Novo Nordisk AS | $15 | Research payment | In-kind items and services | NN7415-4307 | 2020 | |
| 2020-12-22 | Novo Nordisk AS | $15 | Research payment | In-kind items and services | NN7415-4307 | 2020 | |
| 2020-12-22 | Novo Nordisk AS | $15 | Research payment | In-kind items and services | NN7415-4307 | 2020 | |
| 2020-12-22 | Novo Nordisk AS | $15 | Research payment | In-kind items and services | NN7415-4307 | 2020 | |
| 2020-12-22 | Novo Nordisk AS | $15 | Research payment | In-kind items and services | NN7415-4307 | 2020 | |
| 2020-12-22 | Novo Nordisk AS | $15 | Research payment | In-kind items and services | NN7415-4307 | 2020 | |
| 2020-12-22 | Novo Nordisk AS | $15 | Research payment | In-kind items and services | NN7415-4307 | 2020 | |
| 2020-12-22 | Novo Nordisk AS | $15 | Research payment | In-kind items and services | NN7415-4307 | 2020 | |
| 2020-12-22 | Novo Nordisk AS | $15 | Research payment | In-kind items and services | NN7415-4307 | 2020 | |
| 2020-12-21 | Medtronic Vascular, Inc. | $18,513 | Research payment | Cash or cash equivalent | APOLLO Trial | 2020 | |
| 2020-12-21 | Medtronic Vascular, Inc. | $18,513 | Research payment | Cash or cash equivalent | APOLLO Trial | 2020 | |
| 2020-12-21 | ABBVIE INC. | $950 | Research payment | Cash or cash equivalent | M16-123 | 2020 | |
| 2020-12-21 | Kite Pharma, Inc. | $524 | Research payment | Cash or cash equivalent | Tecartus Drug, CELLT | A Multicenter, Open-label Expanded Access Study of KTE-X19 in Subjects with B-Cell Malignancies | 2020 |
| 2020-12-21 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4321 | 2020 |
| 2020-12-19 | Genentech, Inc. | $1,613 | Research payment | Cash or cash equivalent | Herceptin Biological, BioOncology | MY PATHWAY | 2020 |
| 2020-12-18 | Genentech, Inc. | $16,476 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | GEN EXTEND | 2020 |
| 2020-12-18 | Incyte Corporation | $14,288 | Research payment | Cash or cash equivalent | Noninterventional Epigenomic Mapping of CD34 plus Cells From Healthy Participants and Patients With Myelofibrosis (MF) a | 2020 | |
| 2020-12-18 | Incyte Corporation | $7,244 | Research payment | Cash or cash equivalent | Noninterventional Epigenomic Mapping of CD34 plus Cells From Healthy Participants and Patients With Myelofibrosis (MF) a | 2020 | |
| 2020-12-18 | Incyte Corporation | $4,829 | Research payment | Cash or cash equivalent | Noninterventional Epigenomic Mapping of CD34 plus Cells From Healthy Participants and Patients With Myelofibrosis (MF) a | 2020 | |
| 2020-12-18 | Medical Device Business Services, Inc. | $4,736 | Research payment | Cash or cash equivalent | Safety and Effectiveness Evaluation of the Multi-Electrode Radiofrequency Balloon Catheter for the Treatment of Symptoma | 2020 | |
| 2020-12-18 | Abbott Laboratories | $3,500 | Research payment | Cash or cash equivalent | Amplatzer Amulet LAAO Device, Cardiac Arrhythmias and Heart Failure | Clinical Trial of Atrial Fibrillation Patients Comparing Left Atrial Appendage Occlusion Therapy to Non-vitamin K Antago | 2020 |
| 2020-12-18 | Abbott Laboratories | $2,521 | Research payment | Cash or cash equivalent | Amplatzer Amulet LAAO Device, Cardiac Arrhythmias and Heart Failure | Clinical Trial of Atrial Fibrillation Patients Comparing Left Atrial Appendage Occlusion Therapy to Non-vitamin K Antago | 2020 |
| 2020-12-18 | IRONWOOD PHARMACEUTICALS, INC | $2,500 | Research payment | Cash or cash equivalent | C3718-301 | 2020 | |
| 2020-12-18 | Zealand Pharma A/S | $2,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Dasiglucagon Device, Type I Diabetus | 2020 | |
| 2020-12-18 | IRONWOOD PHARMACEUTICALS, INC | $2,000 | Research payment | Cash or cash equivalent | C3718-301 | 2020 | |
| 2020-12-18 | IRONWOOD PHARMACEUTICALS, INC | $1,500 | Research payment | Cash or cash equivalent | C3718-301 | 2020 | |
| 2020-12-18 | W. L. Gore & Associates, Inc. | $1,290 | Research payment | Cash or cash equivalent | Product in Development Device, Devices | Evaluation of the GORE TAG Thoracic Branch Endoprosthesis (TBE Device) in the Treatment of Lesions of the Aortic Arch an | 2020 |
| 2020-12-18 | Novo Nordisk AS | $30 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4321 | 2020 |
| 2020-12-18 | Novo Nordisk AS | $21 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4321 | 2020 |
| 2020-12-18 | Novo Nordisk AS | $18 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4321 | 2020 |
| 2020-12-18 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4321 | 2020 |
| 2020-12-18 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4321 | 2020 |
| 2020-12-18 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4321 | 2020 |
| 2020-12-18 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4321 | 2020 |
| 2020-12-17 | JAZZ PHARMACEUTICALS INC. | $110,092 | Research payment | In-kind items and services | VYXEOS Drug, HEMATOLOGY/ONCOLOGY | V-FAST: A PHASE 1B MASTER TRIAL TO INVESTIGATECPX-351 COMBINED WITH VARIOUS TARGETED AGENTS IN SUBJECTS WITH PREVIOUSLY | 2020 |
| 2020-12-17 | Amgen Inc. | $61,341 | Research payment | In-kind items and services | Vectibix Biological, Oncology | Phase II trial of panitumumab, nivolumab and ipilimumab for KRAS/NRAS/BRAF wild-type MSS refractory metastatic colorecta | 2020 |
| 2020-12-17 | Exelixis Inc. | $27,547 | Research payment | Cash or cash equivalent | Cabozantinib Drug, Oncology | A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus | 2020 |
| 2020-12-17 | ABBVIE INC. | $13,833 | Research payment | Cash or cash equivalent | M15-570 | 2020 | |
| 2020-12-17 | Edwards Lifesciences Corporation | $8,854 | Research payment | Cash or cash equivalent | Early-TAVR Trial #2016-07 | 2020 | |
| 2020-12-17 | Exelixis Inc. | $8,291 | Research payment | Cash or cash equivalent | Cabozantinib Drug, Oncology | A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus | 2020 |
| 2020-12-17 | Amneal Pharmaceuticals LLC | $6,820 | Research payment | Cash or cash equivalent | IR CD-LD Drug, NEUROLOGY | A RANDOMIZED CONTROLLED STUDY TO COMPARE THE SAFETY AND EFFICACY OF IPX203 WITH IMMEDIATE-RELEASE CARBIDOPA-LEVODOPA IN | 2020 |
| 2020-12-17 | Amneal Pharmaceuticals LLC | $5,061 | Research payment | Cash or cash equivalent | IR CD-LD Drug, NEUROLOGY | A RANDOMIZED CONTROLLED STUDY TO COMPARE THE SAFETY AND EFFICACY OF IPX203 WITH IMMEDIATE-RELEASE CARBIDOPA-LEVODOPA IN | 2020 |
| 2020-12-17 | Merck Sharp & Dohme LLC | $4,272 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Adv | 2020 |
| 2020-12-17 | Travere Therapeutics, Inc. | $3,397 | Research payment | Cash or cash equivalent | (820) Cholbam Drug, Hepatology | The Replace Registry | 2020 |
| 2020-12-17 | Merck Sharp & Dohme LLC | $2,902 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized Phase 3 Study Evaluating Cystectomy with Perioperative Pembrolizumab and Cystectomy with Perioperative Enfo | 2020 |
| 2020-12-17 | Stryker Corporation | $2,553 | Research payment | Cash or cash equivalent | SURPASS Device, FLOW DIVERTER | THE SURPASS INTRACRANIAL ANEURYSM EMBOLIZATION SYSTEM PIVOT TRIAL (SCENT) | 2020 |
| 2020-12-17 | ABBVIE INC. | $2,000 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M14-430 | 2020 |
| 2020-12-17 | ABBVIE INC. | $2,000 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M14-430 | 2020 |
| 2020-12-17 | Karyopharm Therapeutics Inc. | $1,613 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | 8602801 | 2020 |
| 2020-12-17 | Takeda Pharmaceuticals U.S.A., Inc. | $1,613 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 4 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ENTYVIO (VEDOLIZUMAB | 2020 | |
| 2020-12-17 | ABBVIE INC. | $1,500 | Research payment | Cash or cash equivalent | SKYRIZI Biological, IMMUNOLOGY | M16-066 | 2020 |
| 2020-12-17 | Merck Sharp & Dohme LLC | $1,454 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized Phase 3 Study Evaluating Cystectomy with Perioperative Pembrolizumab and Cystectomy with Perioperative Enfo | 2020 |
| 2020-12-17 | Daiichi Sankyo Inc. | $811 | Research payment | Cash or cash equivalent | Enhertu Drug, Oncology | DS8201-A-U302 | 2020 |
| 2020-12-17 | Merck Sharp & Dohme LLC | $800 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized Phase 3 Study Evaluating Cystectomy with Perioperative Pembrolizumab and Cystectomy with Perioperative Enfo | 2020 |
| 2020-12-17 | ABBVIE INC. | $645 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M14-234 | 2020 |
| 2020-12-17 | Karyopharm Therapeutics Inc. | $297 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | 8602801 | 2020 |
| 2020-12-17 | Merck Sharp & Dohme LLC | $133 | Research payment | In-kind items and services | ZINPLAVA Biological, INFECTIOUS DISEASE | Protocol Title A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerability, Phar | 2020 |
| 2020-12-17 | E.R. Squibb & Sons, L.L.C. | $73 | Research payment | Cash or cash equivalent | Ph III MIBC Neoadjuvant 1L Bladder IDO Nivo chemo | 2020 | |
| 2020-12-16 | ABBVIE INC. | $122,928 | Research payment | In-kind items and services | VENCLEXTA Drug, ONCOLOGY | A16-578 | 2020 |
| 2020-12-16 | Boehringer Ingelheim Pharmaceuticals, Inc. | $70,653 | Research payment | Cash or cash equivalent | Efficacy of short term dabigatran etexilate follow | 2020 | |
| 2020-12-16 | Abbott Laboratories | $30,000 | Research payment | Cash or cash equivalent | Alinity HbA1c Device, Diagnostics | Performance Assesment of the Abbott Hemoglobin A1c assay on Alinity | 2020 |
| 2020-12-16 | Merck Sharp & Dohme LLC | $18,746 | Research payment | Cash or cash equivalent | MK-6482 Drug, ONCOLOGY | An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma | 2020 |
| 2020-12-16 | PFIZER INC. | $6,745 | Research payment | Cash or cash equivalent | ROBO2 ESOE | 2020 | |
| 2020-12-16 | Bolton Medical Inc | $1,358 | Research payment | Cash or cash equivalent | RelayPro- IP-0018-16 Device, Device | RelayPro- IP-0018-16 | 2020 |
| 2020-12-16 | SK Life Science, Inc. | $642 | Research payment | Cash or cash equivalent | Cenobamate Drug, Neurology | 059566 | 2020 |
| 2020-12-16 | SK Life Science, Inc. | $576 | Research payment | Cash or cash equivalent | Cenobamate Drug, Neurology | 059566 | 2020 |
| 2020-12-16 | Kite Pharma, Inc. | $524 | Research payment | Cash or cash equivalent | Yescarta Drug, CELLT | A Phase 2 Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination wit | 2020 |
| 2020-12-16 | Bolton Medical Inc | $400 | Research payment | Cash or cash equivalent | RelayPro- IP-0018-16 Device, Device | RelayPro- IP-0018-16 | 2020 |
| 2020-12-16 | Cochlear Americas | $398 | Research payment | In-kind items and services | Nucleus Device, Implantable hearing solution | Nucleus Hybrid L24 Implant System New Enrollment Post Approval Study | 2020 |
| 2020-12-15 | BioMarin Pharmaceutical Inc. | $11,778 | Research payment | Cash or cash equivalent | A Phase 2 Open-Label Long-Term Extension Study to Evaluate the Safety and Efficacy of BMN 111 in Children with Achondrop | 2020 | |
| 2020-12-15 | CSL Behring | $11,414 | Research payment | Cash or cash equivalent | Haegarda Biological, Immunology | A Double-blind, Randomized-withdrawal, Placebo-controlled Study to Evaluate the Efficacy and Safety of Human Plasma-deri | 2020 |
| 2020-12-15 | Takeda Pharmaceuticals U.S.A., Inc. | $10,210 | Research payment | Cash or cash equivalent | A PHASE 1/2 STUDY OF THE SAFETY, PHARMACOKINETICS, AND ANTI-TUMOR ACTIVITY OF THE ORAL EGFR/HER2 INHIBITOR TAK-788 (AP32 | 2020 | |
| 2020-12-15 | Cumberland Pharmaceuticals, Inc. | $9,568 | Research payment | Cash or cash equivalent | Milrinone (127) | 2020 | |
| 2020-12-15 | Cumberland Pharmaceuticals, Inc. | $9,568 | Research payment | Cash or cash equivalent | Milrinone (127) | 2020 | |
| 2020-12-15 | Allergan, Inc. | $4,120 | Research payment | Cash or cash equivalent | A multicenter, open-label, single arm study in patients with open angle glaucoma or ocular hypertension who have not had | 2020 | |
| 2020-12-15 | Exelixis Inc. | $3,038 | Research payment | Cash or cash equivalent | Cabozantinib Drug, Oncology | A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus | 2020 |
| 2020-12-15 | EMD Serono, Inc. | $1,978 | Research payment | Cash or cash equivalent | Bavencio Drug, Oncology | A Multicenter, Open-Label, Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of t | 2020 |
| 2020-12-15 | Novo Nordisk AS | $1,000 | Research payment | Cash or cash equivalent | COR-001-02 | 2020 | |
| 2020-12-15 | EMD Serono, Inc. | $666 | Research payment | Cash or cash equivalent | Tepotinib Drug, Oncology | A Phase II single-arm trial to investigate tepotinib in advanced (Stage IIIb and IV) non-small cell lung cancer with MET | 2020 |
| 2020-12-15 | EMD Serono, Inc. | $264 | Research payment | Cash or cash equivalent | Tepotinib Drug, Oncology | A Phase II single-arm trial to investigate tepotinib in advanced (Stage IIIb and IV) non-small cell lung cancer with MET | 2020 |
| 2020-12-14 | Genentech, Inc. | $56,460 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | GENERATION HD1 | 2020 |
| 2020-12-14 | Genentech, Inc. | $24,695 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | GEN EXTEND | 2020 |
| 2020-12-14 | ABBVIE INC. | $1,300 | Research payment | Cash or cash equivalent | M19-530 | 2020 | |
| 2020-12-14 | Novo Nordisk AS | $432 | Research payment | In-kind items and services | RYBELSUS Drug, Diabetes | EX9924-4473 | 2020 |
| 2020-12-14 | Novo Nordisk AS | $432 | Research payment | In-kind items and services | RYBELSUS Drug, Diabetes | EX9924-4473 | 2020 |
| 2020-12-14 | Novo Nordisk AS | $432 | Research payment | In-kind items and services | RYBELSUS Drug, Diabetes | EX9924-4473 | 2020 |
| 2020-12-14 | Novo Nordisk AS | $432 | Research payment | In-kind items and services | RYBELSUS Drug, Diabetes | EX9924-4473 | 2020 |
| 2020-12-14 | Novo Nordisk AS | $432 | Research payment | In-kind items and services | RYBELSUS Drug, Diabetes | EX9924-4473 | 2020 |
| 2020-12-14 | Novo Nordisk AS | $432 | Research payment | In-kind items and services | RYBELSUS Drug, Diabetes | EX9924-4473 | 2020 |
| 2020-12-14 | Novo Nordisk AS | $432 | Research payment | In-kind items and services | RYBELSUS Drug, Diabetes | EX9924-4473 | 2020 |
| 2020-12-14 | Novo Nordisk AS | $432 | Research payment | In-kind items and services | RYBELSUS Drug, Diabetes | EX9924-4473 | 2020 |
| 2020-12-14 | Novo Nordisk AS | $432 | Research payment | In-kind items and services | RYBELSUS Drug, Diabetes | EX9924-4473 | 2020 |
| 2020-12-14 | Novo Nordisk AS | $432 | Research payment | In-kind items and services | RYBELSUS Drug, Diabetes | EX9924-4473 | 2020 |
| 2020-12-14 | Novo Nordisk AS | $432 | Research payment | In-kind items and services | RYBELSUS Drug, Diabetes | EX9924-4473 | 2020 |
| 2020-12-14 | Novo Nordisk AS | $432 | Research payment | In-kind items and services | RYBELSUS Drug, Diabetes | EX9924-4473 | 2020 |
| 2020-12-14 | Novo Nordisk AS | $432 | Research payment | In-kind items and services | RYBELSUS Drug, Diabetes | EX9924-4473 | 2020 |
| 2020-12-14 | Novo Nordisk AS | $432 | Research payment | In-kind items and services | RYBELSUS Drug, Diabetes | EX9924-4473 | 2020 |
| 2020-12-14 | Novo Nordisk AS | $432 | Research payment | In-kind items and services | RYBELSUS Drug, Diabetes | EX9924-4473 | 2020 |
| 2020-12-11 | GW Research Limited | $12,500 | Research payment | Cash or cash equivalent | GWRE166121 | 2020 | |
| 2020-12-11 | Takeda Pharmaceuticals U.S.A., Inc. | $5,000 | Grant | Cash or cash equivalent | 2020 | ||
| 2020-12-11 | GW Research Limited | $4,930 | Research payment | Cash or cash equivalent | GWRE166121 | 2020 | |
| 2020-12-11 | GW Research Limited | $2,500 | Research payment | Cash or cash equivalent | GWRE166121 | 2020 | |
| 2020-12-11 | GW Research Limited | $1,500 | Research payment | Cash or cash equivalent | GWRE166121 | 2020 | |
| 2020-12-11 | Genentech, Inc. | $811 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | 1L MTNBC IPATASERTIB TECENTRIQ PACLITAXEL | 2020 |
| 2020-12-11 | Merck Sharp & Dohme LLC | $744 | Research payment | In-kind items and services | PNEUMOVAX 23 Biological, VACCINE | Pneumococcal pNeumonia Epidemiology, Urine serotyping, and Mental Outcomes. The PNEUMO Study. | 2020 |
| 2020-12-11 | GW Research Limited | $500 | Research payment | Cash or cash equivalent | GWRE166121 | 2020 | |
| 2020-12-10 | GE HEALTHCARE | $111,000 | Research payment | In-kind items and services | AMYLOID IMAGING TO PREVENT ALZHEIMERS DISEASE | 2020 | |
| 2020-12-10 | Veloxis Pharmaceuticals, Inc. | $102,728 | Research payment | Cash or cash equivalent | Envarsus Drug, Immunosuppressant | Early Use of Longacting Tacrolimus in Lung Transplant Recipients | 2020 |
| 2020-12-10 | PFIZER INC. | $1,750 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2020 | ||
| 2020-12-10 | ABBVIE INC. | $1,500 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M14-430 | 2020 |
| 2020-12-10 | MDD US Operations, LLC | $1,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | APOKYN Drug, Neurology | 2020 | |
| 2020-12-10 | PFIZER INC. | $670 | Research payment | Cash or cash equivalent | XELJANZ Drug, GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | A MULTICENTER OPENLABEL STUDY OF CP690550 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS | 2020 |
| 2020-12-10 | ABBVIE INC. | $386 | Research payment | Cash or cash equivalent | SKYRIZI Biological, IMMUNOLOGY | M16-000 | 2020 |
| 2020-12-09 | Genentech, Inc. | $14,500 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | STUDY OF CABOZANTINIB WITH ATEZOLIZUMAB AS NEOADJUVANT TREATMENT FOR MUSCLE INVASIVE BLADDER CA | 2020 |
| 2020-12-09 | SEAGEN INC. | $4,058 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | 2020 |
| 2020-12-09 | Merck Sharp & Dohme LLC | $3,443 | Research payment | Cash or cash equivalent | MK-6482 Drug, ONCOLOGY | An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma | 2020 |
| 2020-12-09 | Deciphera Pharmaceuticals Inc. | $645 | Research payment | Cash or cash equivalent | QINLOCK Drug, ONCOLOGY | INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE | 2020 |
| 2020-12-09 | Merck Sharp & Dohme LLC | $558 | Research payment | In-kind items and services | PNEUMOVAX 23 Biological, VACCINE | Pneumococcal pNeumonia Epidemiology, Urine serotyping, and Mental Outcomes. The PNEUMO Study. | 2020 |
| 2020-12-09 | Deciphera Pharmaceuticals Inc. | $500 | Research payment | Cash or cash equivalent | QINLOCK Drug, ONCOLOGY | INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE | 2020 |
| 2020-12-08 | JAZZ PHARMACEUTICALS INC. | $25,358 | Research payment | Cash or cash equivalent | VYXEOS Drug, HEMATOLOGY/ONCOLOGY | V-FAST: A PHASE 1B MASTER TRIAL TO INVESTIGATE CPX351COMBINED WITH VARIOUS TARGETED AGENTS IN SUBJECTS WITH PREVIOUSLY U | 2020 |
| 2020-12-08 | Genentech, Inc. | $6,122 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PHASE III STUDY OF BALOVAPTAN IN ADULTS WITH ASD | 2020 |
| 2020-12-08 | BioMarin Pharmaceutical Inc. | $3,645 | Research payment | Cash or cash equivalent | Palynziq Drug, PKU | An Open-label Extension Study to Evaluate the Safety and Efficacy of Subcutaneous Injections of Pegvaliase 40 mgday Dos | 2020 |
| 2020-12-08 | Ultragenyx Pharmaceutical Inc. | $2,884 | Research payment | Cash or cash equivalent | Crysvita Drug, XLH Metabolic Bone Disorder | UX023-CL401 | 2020 |
| 2020-12-08 | Bayer Healthcare Pharmaceuticals Inc. | $2,230 | Research payment | Cash or cash equivalent | Non-Covered | BAY94-8862 ph 3 conventional in diabetic nephropathy | 2020 |
| 2020-12-08 | BioMarin Pharmaceutical Inc. | $2,025 | Research payment | Cash or cash equivalent | Palynziq Drug, PKU | An Open-label Extension Study to Evaluate the Safety and Efficacy of Subcutaneous Injections of Pegvaliase 40 mgday Dos | 2020 |
| 2020-12-08 | Dendreon Pharmaceuticals LLC | $2,000 | Research payment | Cash or cash equivalent | PROVENGE Drug, CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | OPEN- LABEL TRIAL OF SIPULEUCEL-T ADMINISTERED TO ACTIVE SURVEILLANCE PATIENTS FOR NEWLY DIAGNOSED PROSTATE CANCER (PROV | 2020 |
| 2020-12-08 | Bayer Healthcare Pharmaceuticals Inc. | $1,883 | Research payment | Cash or cash equivalent | Non-Covered | BAY94-8862 ph 3 conventional in diabetic nephropathy | 2020 |
The latest 200 records of 3,812.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Nashville-Davidson, TN, county Davidson County, TN, state Tennessee; placed by its city name.
| Measure | Place (city or town) Nashville-Davidson, TN | County Davidson County, TN | State Tennessee |
|---|---|---|---|
| Population B01003 | 690,130 | 715,388 | 7,066,383 |
| Population, 2020 census P1 | 689,447 | 715,884 | 6,910,840 |
| Median age B01002 | 34.5 | 34.6 | 38.9 |
| Under 18 B01001 | 20.7% | 20.7% | 22.2% |
| 65 and over B01001 | 12.7% | 12.9% | 17.1% |
| Households B11001 | 313,513 | 324,907 | 2,824,277 |
| Foreign born B05002 | 15.3% | 15.0% | 6.1% |
| Median household income B19013 | $77,371 | $77,853 | $69,595 |
| Median family income B19113 | $98,376 | $99,460 | $87,314 |
| Per capita income B19301 | $49,061 | $50,640 | $39,437 |
| Poverty rate B17001 | 14.1% | 13.9% | 13.8% |
| Unemployment rate B23025 | 4.5% | 4.5% | 4.7% |
| Civilian labor force B23025 | 407,433 | 421,061 | 3,527,571 |
| Mean commute (minutes) B08013 | 24.7 | 24.7 | 25.7 |
| Bachelor's degree or higher B15003 | 48.0% | 48.4% | 31.1% |
| Housing units B25001 | 344,794 | 357,113 | 3,143,670 |
| Owner-occupied B25003 | 52.4% | 52.8% | 66.9% |
| Renters B25003 | 47.6% | 47.2% | 33.1% |
| Median home value B25077 | $413,600 | $417,400 | $286,700 |
| Median gross rent B25064 | $1,586 | $1,582 | $1,189 |
| White, not Hispanic B03002 | 52.6% | 53.2% | 71.0% |
| Black B03002 | 24.5% | 24.3% | 15.4% |
| Hispanic or Latino B03002 | 14.1% | 13.9% | 7.4% |
| Asian B03002 | 3.5% | 3.4% | 1.9% |
| American Indian and Alaska Native B03002 | 0.1% | 0.1% | 0.1% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Nashville-Davidson, TN.
Comments